{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-001490","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.242879+00:00","generated_at":"2026-06-07T04:06:08.567355+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Adicet Bio gets FDA IND clearance for ADI-001 in lupus nephritis; plans Phase 1 in Q2 2024","bullets":["FDA cleared IND for ADI-001 in lupus nephritis Dec 2023; Phase 1 start planned Q2 2024.","Focusing ADI-001 Phase 1 GLEAN enrollment on MCL patients; June 2023 data showed 80% CR rate.","ADI-001 clinical update expected 2H 2024; evaluating accelerated approval pathway for MCL.","ADI-270 IND submission for renal cell carcinoma planned Q2 2024 after positive pre-IND meeting.","Cash and equivalents expected to fund operations into second half of 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-001490","json":"https://secwatch.observer/filing/0000950170-24-001490.json","markdown":"https://secwatch.observer/filing/0000950170-24-001490.md","text":"https://secwatch.observer/filing/0000950170-24-001490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024001490/0000950170-24-001490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024001490/acet-20240104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:06:08.567355+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}